Nurix Therapeutics (NRIX) Income towards Parent Company (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Income towards Parent Company data on file, last reported at -$87.2 million in Q1 2026.

• Income towards Parent Company for Q1 2026 came in at -$87.2 million, down 54.7% year-over-year; the trailing twelve-month figure through Feb 2026 was -$295.3 million (down 41.69% YoY), and the FY2025 annual result was -$264.5 million, down 36.62% from the prior year.
• Income towards Parent Company eased to -$87.2 million in Q1 2026 per NRIX's latest filing, from -$78.2 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at -$24.3 million in Q2 2023 and troughed at -$87.2 million in Q1 2026.
• A 5-year average of -$51.1 million and a median of -$45.4 million in 2022 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2023 and 2024: Income towards Parent Company surged 46.53% in 2023, then slumped 83.49% in 2024.
• A 5-year view of Income towards Parent Company shows it stood at -$46.7 million in 2022, then gained by 10.19% to -$42.0 million in 2023, then plunged by 39.55% to -$58.5 million in 2024, then slumped by 33.6% to -$78.2 million in 2025, then fell by 11.45% to -$87.2 million in 2026.
• Business Quant data shows NRIX's Income towards Parent Company at -$87.2 million in Q1 2026, -$78.2 million in Q4 2025, and -$86.4 million in Q3 2025.